Thursday, March 14, 2019
It’s an exciting time in the world of triple-negative breast cancer (TNBC), with treatments becoming more personalized to individual cancer subtypes, explained Adam Brufsky, MD, PhD. Brufsky, a professor of medicine and associate director for clinical investigation at the University of Pittsburgh Medical Center Hillman Cancer Center, discussed treatments for BRCA-positive breast cancer at the 2019 Miami Breast Cancer Conference.
“Within the last year or so, we now have at least 2, and probably 3 things, that we’re going to be able to treat people [who have] TNBC with, and quite effectively with metastatic disease,” Brufsky said. The presentation occurred the day after the Food and Drug Administration approved atezolizumab (Tecentriq) for unresectable locally advanced or metastatic PD-L1–positive TNBC—an exciting advancement, bringing the first-ever immune checkpoint inhibitor into the breast cancer space.
Read the full article here: